Troubled Cempra Inc. and privately held Melinta Therapeutics Inc. – which is nearing the launch of its first product – are merging in a deal that combines two antibiotic pipelines, brings Melinta an established commercial team and may buy Cempra more time to resolve the regulatory path forward for its community-acquired bacterial pneumonia candidate solithromycin.
Announcing the merger during its second quarter earnings call Aug. 9, Cempra said the combined company, to be called Melinta...








